Business Context and Reporting Period
Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: A diversified professional staffing firm operating in two segments: Lab Support (life science staffing) and Healthcare Staffing (Nurse Travel and Medical Financial & Allied). The company provides contract professionals, contract-to-permanent placements, and direct hires.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Revenues | $75,678,000 | $211,037,000 |
| Gross Profit | $20,780,000 | $57,032,000 |
| Gross Margin | 27.5% | 27.0% |
| Operating Income | $3,514,000 | $6,336,000 |
| Net Income | $2,699,000 | $4,915,000 |
| Diluted EPS | $0.10 | $0.18 |
| Cash & Equivalents | $30,394,000 | $30,394,000 (Balance Sheet) |
| Restricted Cash | $5,178,000 | $5,178,000 (Balance Sheet) |
| Working Capital | $57,788,000 | N/A |
| Total Debt | $0 | $0 |
Note: The company has no long-term debt or borrowing facilities in place as of the reporting date.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14.7% year-over-year (YoY) for the quarter and 21.9% YoY for the nine-month period. Growth was driven by a 12.5% increase in the average number of contract professionals on assignment and a 5.6% increase in average bill rates.
- Profitability Turnaround: The company returned to profitability. For the nine months ended September 30, 2006, the company reported a net income of $4.9 million compared to a net loss of $0.9 million in the same period in 2005.
- Segment Performance:
- Lab Support: Revenues up 14.9% (quarter) and 19.0% (nine months). Gross margin improved 40 basis points to 32.7%.
- Healthcare Staffing: Revenues up 14.6% (quarter) and 24.0% (nine months). Nurse Travel revenues grew 13.3% (quarter) and 21.8% (nine months).
- Expense Management: Selling, General, and Administrative (SG&A) expenses increased 5.5% YoY for the quarter, primarily due to the adoption of FAS 123R (stock-based compensation) and increased field headcount. However, SG&A as a percentage of revenue decreased from 24.8% to 22.8%.
- Cash Flow: Net cash provided by operating activities improved significantly to $12.0 million for the nine months ended September 30, 2006, compared to $3.4 million in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management expects continued year-over-year revenue growth in the fourth quarter of 2006, assuming stable labor markets and no loss of major clients. The company is focusing on expanding direct placements and growing newer service lines (Health Information Management, Clinical Research, Engineering).
- Capital Expenditures: The company expects to incur approximately $3.7 million to $4.0 million in capital expenditures for 2006 related to software initiatives (PeopleSoft and Vurv Technology) and leasehold improvements. $3.05 million has already been incurred.
- Financing Activity: On November 1, 2006, the company filed a preliminary prospectus to sell 6,650,000 shares of common stock. Proceeds are intended for acquisitions, working capital, and capital expenditures.
- Tax Position: The company maintains a valuation allowance against net deferred income tax assets. Management anticipates the reversal of this allowance may occur as early as the fourth quarter of 2006 if sustained profitability is demonstrated.
- Risks: Key risks include demand for services, ability to retain qualified staffing consultants and contract professionals, competition, and the successful integration of acquisitions. Foreign currency risk is considered immaterial.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the impact of FAS 123R adoption on future earnings, as stock-based compensation expense increased significantly ($1.875 million for the nine months ended Sep 30, 2006 vs. $0.167 million in 2005).
- Valuation Allowance Reversal: Monitor the fourth quarter of 2006 for the potential reversal of the valuation allowance on deferred tax assets, which would materially impact net income.
- Capital Expenditure Execution: Track the completion of Phase II of the Vurv Technology implementation and PeopleSoft modules scheduled for Q1 2007 to ensure projected productivity gains are realized.
- Equity Offering: Confirm the status and pricing of the proposed 6.65 million share offering filed in November 2006 to assess potential dilution.
- Workers' Compensation Liability: Review the adequacy of the accrued workers' compensation liability ($3.856 million), which is partially self-insured and collateralized by restricted cash.